Evaluation of immunological status in tumor-bearing dogs

Itoh, Hiroshi; Horiuchi, Yutaka; Nagasaki, Teppei; Sakonju, Iwao; Kakuta, Tomoko; Fukushima, U; Uchide, Tsuyoshi; Yamashita, Mariko; Kuwabara, Masato; Yusa, Sei-ichi; Takase, Katsuaki

doi:10.1016/j.vetimm.2009.04.020

Cited by 27 publications

(34 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results contrast with the increase in WBC counts previously described in dogs with cancer. 6,17 White blood cell counts in dogs with distant metastases are significantly higher than in dogs without metastases. 17 The increase in WBC count has been explained by a neutrophil leukocytosis that could be induced by infection, inflammation, and tissue necrosis associated with malignant neoplasms.…”

mentioning

confidence: 95%

“…[4][5][6]11,15,17 It has been described that tumor-bearing dogs have a higher number of leukocytes than normal dogs. 6 Absolute cell and relative percentage of cluster of differentiation (CD)3+ T cells, CD4+ T helper (Th) cells, CD8+ T cytotoxic (Tc) cells, and CD21+ B cells in dogs with tumors are notably decreased in comparison with healthy dogs. 17 In addition, tumorbearing dogs show a significant increase of plasma interleukin 6 and transforming growth factor-beta activities.…”

mentioning

confidence: 99%

“…Studies available describe immune status by means of peripheral lymphocyte subsets in dogs with cancer, 6,11,14,17 hyperadrenocorticism, 10 leishmaniosis, 1,9 or ehrlichiosis. 8,16 The data presented in the current study showed that immunophenotype of peripheral blood lymphocytes in diseased dogs may be altered.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Comparative study of peripheral blood leukocytes in healthy dogs and in dogs with cancer and inflammatory diseases

et al. 2014

View full text Add to dashboard Cite

Abstract. In the present study, the peripheral blood lymphocyte subset distribution was compared between healthy dogs and dogs with chronic gastrointestinal disease, dental and skin conditions, and cancer. The immunophenotype of the group with chronic gastrointestinal disease and the group with dental and skin conditions showed no statistically significant differences with other groups of healthy or diseased dogs. When compared with healthy dogs, animals with cancer showed significantly lower absolute values of T cytotoxic cells (CD3+, CD8+) and lymphocytes that express major histocompatibility complex (MHC) class II (MHC-II+) in peripheral blood. The results suggest that peripheral blood immunophenotype is mainly altered in dogs with cancer but not in other diseases. Further studies are required to evaluate the clinical relevance of these findings.

show abstract

mentioning

confidence: 95%

mentioning

confidence: 99%

See 1 more Smart Citation

Comparative study of peripheral blood leukocytes in healthy dogs and in dogs with cancer and inflammatory diseases

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Serum α1-acid glycoprotein (AGP) concentrations are increased in various inflammatory disorders, such as inflammation associated with infectious diseases, some immunemediated disorders, trauma, other conditions with acute inflammation, and some malignant tumors (Ogilvie et al 1993;Hahn et al 1999;Itoh et al 2009;Yuki et al 2010). Induction and expression of AGP is controlled by inflammatory cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α, and glucocorticoids, which are synthesized mainly in the liver (Itoh et al 1997;Fournier et al 2000).…”

Section: Introductionmentioning

confidence: 99%

Investigation of serum concentrations and immunohistochemical localization of α1-acid glycoprotein in tumor dogs

et al. 2010

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to measure the dynamics of serum α1-acid glycoprotein (AGP) concentration in dogs with various tumors, and to investigate the localization of AGP in some tissues using immunohistochemical staining. Sera were obtained from 171 dogs bearing tumors of various types. Serum AGP concentration was measured by single radial immunodiffusion. Tumors occurring in the liver and spleen were also investigated immunohistochemically using anti-canine AGP antibody. Mean serum AGP levels were 749 ± 602 mg/L in dogs with carcinoma (n = 39), 1,014 ± 971 mg/L with sarcoma (n = 18), and 887 ± 935 mg/L with round cell tumors (n = 46), all significantly higher than serum AGP level in healthy dogs (n = 137, 364 ± 106 mg/L). Mean serum AGP levels were significantly higher than in healthy dogs in complex mammary gland carcinoma (n = 5, 876 ± 721 mg/L), malignant melanoma (n = 7, 1,010 ± 821 mg/L), and hepatocellular carcinoma (n = 5, 936 ± 741 mg/L) among carcinomas, hemangiosarcoma (n = 5, 1,740 ± 1,323 mg/L) among sarcomas, and lymphoma (n = 19, 1,072 ± 965 mg/L) and histiocytic tumor (n = 6, 1,800 ± 1,387 mg/L) among round cell tumors. In an immunohistochemical investigation of AGP localization, both weak and strong staining for anti-AGP antibody were seen in hepatic tissue in dogs with primary non-tumorous lesions originating in the spleen (hematoma) and elevated serum AGP, but all tumor tissue in the spleen was negative. Among dogs with primary tumor lesions of the spleen (hemangiosarcoma) and elevated serum AGP levels, both weak, moderate and strong staining for anti-AGP antibody were seen in hepatic tissue, while strong positive staining was apparent in all tumorous tissue from the spleen. In primary tumor lesions in the liver (hepatocellular carcinoma), both moderate and strong staining for anti-AGP antibody were seen in normal hepatic tissue, and both weak, moderate and strong staining were seen in tumor tissues of the liver. AGP levels thus appear to be elevated in dogs with carcinomas, sarcomas, and round cell tumors. With some of these malignant tumors, localization of AGP in tumor tissue was seen.

show abstract

“…Moreover, the immunological status and expression of specific molecules which modulate the immune response, such as IL-6, TGFbeta or alpha 1-acid glycoprotein (alpha(1)AG), may be also used as a potent diagnostic marker of these malignancies. Itoh et al (2009) investigated differences in the immunological status of dogs with cancers at different stages of development in comparison to normal, healthy animals in relation to the expression of these markers. They showed that the number of leukocytes in the whole blood was higher in dogs with cancer as compared to normal dogs, and this count increased in the more advanced tumours.…”

Section: The Role Of Interleukin In Oncogenesis and Cancer Therapy Inmentioning

confidence: 99%

The immunological, biochemical and molecular bases of canine senescence and carcinogenesis: a review

Woźna¹,

Kempisty²,

Piotrowska³

et al. 2012

Vet. Med. - Czech

View full text Add to dashboard Cite

ABSTRACT:Senescence is a complex set of processes involving several biochemical, molecular and metabolomic changes, including also many disturbances in the immunological system. There are many factors, described as intrinsic and extrinsic (environmental), that may lead to advanced body senescence. In this review, several of the biochemical as well as molecular factors involved in senescence are described. The importance of immunological deficiencies as well as changes in the immunological response after induction of senescence is also highlighted. Furthermore, the molecular basis of canine carcinogenesis in relation to interleukin expression and activation as well as the role of CD leukocyte common antigen in the identification of cancer development and progression, are also described. Keywords: senescence; carcinogenesis; canine List of abbreviations4-HNE = 4-hydroxynonenal, Aβ1-42 = β-amyloid form, AD = Alzheimer disease, alpha(1)AG = alpha 1 acid glycoprotein, bcl-2 = B-cell leukemia 2, BER = base-excision repair, BRCA1 = breast cancer susceptibility gene-1, CD = cluster of differentiation, coating the surface of B lymphocytes and T lymphocytes, CTVT = canine transmissible venereal tumour, FOXP3 = forkhead box P3, scurfin, IFN-gamma = interferon-gamma, IL = interleukin, IVL = intravascular lymphoma, MGT's = mammary gland tumours, MHC = major histocompatibility complex, NFTs = neurofibrillary tangles, NHL = non-Hodgkin's lymphoma, NK = natural killer, OGG1 = 8-oxoguanine glycosylase 1, OSA = osteosarcoma, PAC-1 = first procaspase activating compound, PBLs = peripheral blood lymphocytes, pIL = interleukin plasmids, SLC1A3 = solute carrier family 1 (glial high affinity glutamate transporter), member 3, SOD = superoxide dismutase, TCR = T-cell receptor, TCRBCL = T-cell rich B-cell lymphoma, TGF-beta = transforming growth factor beta, TIL's = tumour-infiltrating lymphocytes, Tregs = T regulatory cells, VEGF = vascular endothelial growth factor

show abstract

Evaluation of immunological status in tumor-bearing dogs

Cited by 27 publications

References 27 publications

Comparative study of peripheral blood leukocytes in healthy dogs and in dogs with cancer and inflammatory diseases

Comparative study of peripheral blood leukocytes in healthy dogs and in dogs with cancer and inflammatory diseases

Investigation of serum concentrations and immunohistochemical localization of α1-acid glycoprotein in tumor dogs

The immunological, biochemical and molecular bases of canine senescence and carcinogenesis: a review

Contact Info

Product

Resources

About